Dyadic Applied BioSolutions expanded its collaboration with Fermbox Bio, a biotech research & manufacturing company developing and delivering bio-based products through precision fermentation and advanced biotechnology tools. The agreement will enable Fermbox Bio to manufacture and commercialize a growing portfolio of Dyadic-developed proteins and enzymes using both the Dapibus and C1 expression systems. Dyadic officials say the company will co-commercialize these products globally to bring scalable, animal-free solutions to life science, food and nutrition, and bioindustrial sectors. The agreement also allows both parties to incorporate products developed on Fermbox Bio’s proprietary microbial platforms into the joint portfolio. “Fermbox will be producing multiple Dyadic-developed proteins and enzymes at a commercial scale,” notes Joe Hazelton, president and COO of Dyadic. “Equally important, this collaboration brings additional products from Fermbox’s other microbial platforms into our joint offering, creating even greater opportunities for both companies.” “This expanded partnership with Dyadic reflects our commitment to build and share value by collaboratively leveraging complementary capabilities to develop and scale a broad pipeline of precision fermentation–derived bioproducts,” adds Subramani Ramachandrappa, CEO of Fermbox Bio. The post Animal-Free Protein and Enzyme Deal Expanded by Dyadic and Fermbox Bio appeared first on GEN – Genetic Engineering and Biotechnology News.
